These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16327325)

  • 1. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.
    Bautista-Arredondo S; Mane A; Bertozzi SM
    AIDS; 2006 Jan; 20(1):101-9. PubMed ID: 16327325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costing of scaling up HIV/AIDS treatment in Mexico.
    Bautista-Arredondo S; Dmytraczenko T; Kombe G; Bertozzi SM
    Salud Publica Mex; 2008; 50 Suppl 4():S437-44. PubMed ID: 19082254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
    Caro JJ; O'Brien JA; Migliaccio-Walle K; Raggio G
    Pharmacoeconomics; 2001 Jan; 19(1):95-104. PubMed ID: 11252549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral chemotherapy.
    Saag MS; Schooley RT
    Curr Clin Top Infect Dis; 1998; 18():154-79. PubMed ID: 9779354
    [No Abstract]   [Full Text] [Related]  

  • 10. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].
    García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M
    Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015.
    Suárez-García I; González J; Berenguer J; García F; Portilla J; Muga R; Moreno S; Jarrín I;
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Nov; 37(9):580-587. PubMed ID: 30982676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiretroviral therapy in HIV infection. Effects of the introduction of new drugs on health care expenditures, 1994-1999].
    Manfredi R; Fiacchi P; Riolo U; Chiodo F
    Recenti Prog Med; 2000 Sep; 91(9):425-9. PubMed ID: 11021163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients.
    Nichols BE; Cele R; Lekodeba N; Tukei B; Ngorima-Mabhena N; Tiam A; Maotoe T; Sejana MV; Faturiyele IO; Chasela C; Rosen S; Fatti G
    J Int AIDS Soc; 2021 Apr; 24(4):e25692. PubMed ID: 33838012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid scaling-up of access to antiretroviral therapy in Mexico: Is it better not to treat?
    Volkow P; Villasis A; Cornejo P; Sierra-Madero J
    AIDS; 2007 Jan; 21(2):261-2. PubMed ID: 17197827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.